Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Bibliographic Details
Main Authors:	Gianluca Mauri, Giorgio Patelli, Viviana Gori, Calogero Lauricella, Benedetta Mussolin, Alessio Amatu, Katia Bencardino, Federica Tosi, Erica Bonazzina, Emanuela Bonoldi, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Oncology
Subjects:	MAP2K1 MEK panitumumab resistance mechanisms colorectal cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1147497/full

Similar Items

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
by: Gianluca Mauri, et al.
Published: (2022-11-01)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
by: Alessio Amatu, et al.
Published: (2022-02-01)

The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer
by: Gianluca Mauri, et al.
Published: (2021-01-01)

Early‐onset colorectal cancer in young individuals
by: Gianluca Mauri, et al.
Published: (2019-02-01)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
by: Vito Amodio, et al.
Published: (2021-05-01)

Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
by: Gianluca Mauri, et al.
Published: (2023-03-01)

Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature
by: Giorgio Patelli, et al.
Published: (2021-02-01)

The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review
by: Roberta Lombardo, et al.
Published: (2020-05-01)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
by: Alessio Amatu, et al.
Published: (2019-07-01)

Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
by: Elio Gregory Pizzutilo, et al.
Published: (2021-05-01)

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
by: Mariangela Russo, et al.
Published: (2018-06-01)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
by: Sara Lonardi, et al.
Published: (2020-10-01)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
by: Alessandro Parisi, et al.
Published: (2021-10-01)

OPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONS
by: L. V. Bolotina
Published: (2015-02-01)

Papulopustular lesions of the face caused by panitumumab: case report and literature review
by: Ravasco Jonathan, et al.
Published: (2018-06-01)

Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer
by: Maria Debora De Pasquale, et al.
Published: (2020-02-01)

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
by: Valentina Giannini, et al.
Published: (2022-01-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
by: Francesca Consoli, et al.
Published: (2020-07-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
by: Gerardo Rosati, et al.
Published: (2022-11-01)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
by: Alexios Matikas, et al.
Published: (2015-03-01)

PRIDE syndrome associated with panitumumab treatment – case report and literature review
by: Magalena Pałdyna, et al.
Published: (2023-05-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
by: Changjing Cai, et al.
Published: (2022-09-01)

Pathologic complete response in metastatic right-sided colon cancer treated with panitumumab and FOLFOX4 chemotherapy regimen
by: Džunić Miljana, et al.
Published: (2022-01-01)

Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report
by: Atsushi Kawasaki, et al.
Published: (2013-05-01)

Panitumumab-associated encephalopathy after accidental intra-arterial application through dislocated Port-a-Cath device in the left ventricle
by: Slaven Pikija, et al.
Published: (2016-11-01)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu
by: Sadaf Aghevlian, et al.
Published: (2020-11-01)

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan
by: Munenobu Kashiwa, et al.
Published: (2021-10-01)

A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040
by: Yuli Wangab, et al.
Published: (2005-04-01)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
by: Rossana Roncato, et al.
Published: (2020-09-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01)

Durable complete response in a patient with metastatic left‐sided colon cancer treated with 5‐fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report
by: Esther Kim, et al.
Published: (2019-07-01)

Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer
by: Valeria Internò, et al.
Published: (2020-09-01)

Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients
by: Gerber Peter, et al.
Published: (2012-02-01)